Market Overview

Jefferies Reiterates Hold Rating, $6 PT for Exelixis

Share:
Related EXEL
9 Biggest Mid-Day Gainers For Monday
Stocks Hitting 52-Week Highs
Might Relypsa Get A Higher Bid? (Seeking Alpha)

In a company update published earlier today, Jefferies & Company, Inc. reiterated its Hold rating and $6.00 price target for Exelixis, Inc. (NASDAQ: EXEL), related to the recent reveal of cabo NRE efficacy data.

Jefferies went on to say “The cabo NRE data, somewhat key for the mCRPC outlook and presented at ASCO, left much to be desired. Despite somewhat intriguing early data in renal and liver cancers for which further exploration is warranted, we remain concerned about cabo's clinical, regulatory and commercial prospects in mCRPC, where investor and EXEL's focus lies.”

Exelixis, Inc. closed yesterday at $4.77.

Latest Ratings for EXEL

DateFirmActionFromTo
Apr 2016Stifel NicolausUpgradesHoldBuy
Jan 2016Leerink SwannUpgradesMarket PerformOutperform
Sep 2014Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for EXEL
View the Latest Analyst Ratings

Posted-In: Jefferies & Company Inc.Analyst Color Reiteration Analyst Ratings

 

Related Articles (EXEL)

View Comments and Join the Discussion!